New flexibility and a new Celgene deal for Jounce

With BMS's acquisition of Celgene nearly complete, the big biotech and Jounce ended an immuno-oncology option deal on Tuesday, giving Jounce control over programs that would have overlapped with BMS's pipeline. But the companies will remain

Read the full 365 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE